Phase II Study of the GI-4000 KRAS Vaccine After Curative Therapy in Patients With Stage I-III Lung Adenocarcinoma Harboring a KRAS G12C, G12D, or G12V Mutation
Title:
Phase II Study of the GI-4000 KRAS Vaccine After Curative Therapy in Patients With Stage I-III Lung Adenocarcinoma Harboring a KRAS G12C, G12D, or G12V Mutation
Author:
Chaft, Jamie E. Litvak, Anya Arcila, Maria E. Patel, Payal D'Angelo, Sandra P. Krug, Lee M. Rusch, Valerie Mattson, Alicia Coeshott, Claire Park, Bernard Apelian, David M. Kris, Mark G. Azzoli, Christopher G.